Oxybutynin

When ATH:
G04BD04

Characteristic.

The white crystalline solid mass with a molecular weight 393,9. Easily soluble in water and acids, relatively little in alkalis.

Pharmacological action.
Spasmolytic, myotropic.

Application.

Neurogenic bladder, idiopathic bladder instability (with frequent urination, incontinence, urination, dysuria and other symptoms); hyperreflexia and detrusor dysfunction; nocturnal enuresis, and neurogenic bladder disorders in children older 5 years.

Contraindications.

Hypersensitivity, glaucoma (closed- and open-), gastrointestinal obstructive disorders, paralytic ileus, expansion of the colon (incl. toxic, complicated by ulcerative colitis), severe colitis, myasthenia (including myasthenia gravis), obstructive uropathy etiology, bowel atony in elderly and debilitated patients, acute bleeding in the instability of the parameters of the cardiovascular system, pregnancy, lactation, childhood (to 5 years).

Pregnancy and breast-feeding.

Category actions result in FDA - B. (The study of reproduction in animals revealed no risk of adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not done.)

Side effects.

Dry mouth, nausea, vomiting, constipation, flatulence, reduced motility of the stomach and intestines, urination disorders (incl. urinary retention), heartbeat, tachycardia, vasodilation, weakness, dizziness, drowsiness or insomnia, anxiety, hallucinations, decreased production of tear fluid, midriaz, increased intraocular pressure, cycloplegia, visual impairment (amblyopia), decreased sweating, impotence, suppression of lactation, allergic reactions (rashes).

Cooperation.

Alcohol and other sedatives increase dizziness and drowsiness.

Overdose.

Symptoms: CNS excitation (anxiety, tremor, irritability, convulsions, delirium, hallucinations), redness of the face, fever, nausea, vomiting, tachycardia, Hypo- or hypertension, respiratory insufficiency, paralysis, coma.

Treatment: the maintenance of respiratory function, induction of vomiting, gastric lavage; possible to use activated charcoal and laxatives; to reverse symptoms of anticholinergic toxicity is prescribed physostigmine; when hyperpyrexia - cold packs, incl. with ice, alcohol rubdown.

Dosing and Administration.

Inside, before meals. The dosage and administration schedule individual. Usually - by 5 mg (1 Table.) 2-3 Times (no more 4) per day for adults and 2 times (no more 3) per day for children over 5 years; the maximum dose - 20 and 15 mg respectively. Older children and possibly the appointment of the initial dose of 2.5-3 mg 2 twice a day with gradual increase to normal. If nocturnal enuresis - the last intake before bedtime.

Precautions.

Use caution when neurocirculatory dystonia, liver and kidney diseases, gipertireoze, CHD, Congestive heart failure, tachycardia, aritmijax, hypertension, DGPŽ (particularly in the initial stages of), nespetsificheskom yazvennom cars, diaphragmatic hernia (incl. associated with gastroesophageal reflux), diarrhea, accompanying incomplete intestinal obstruction (especially in patients with ileo- or colostomy), in old age. During treatment is not recommended to drive and deal with others. activities, require high concentration and the associated risk to life (may develop dizziness and blurred vision). It will be appreciated, that high ambient temperatures often provokes fever and heart weakness (decreased sweating) against the backdrop of oxybutynin.

Cooperation